Drug Profile
YPL 001
Alternative Names: YPL-001Latest Information Update: 29 Sep 2021
Price :
$50
*
At a glance
- Originator Yungjin Pharm Co
- Class Anti-inflammatories; Antiasthmatics; Herbal medicines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Chronic obstructive pulmonary disease
Most Recent Events
- 29 Sep 2021 No development reported - Phase-II for Chronic obstructive pulmonary disease (In the elderly, In adults) in USA (PO) (Yungjin Pharm pipeline, September 2021)
- 29 Sep 2021 Phase-II clinical trials in Chronic obstructive pulmonary disease in South Korea (PO) prior to September 2021 (Yungjin Pharm pipeline, September 2021)
- 24 Oct 2018 Phase II development is ongoing USA (PO) (NCT02272634) (Yungjin Pharmaceutical pipeline, October 2018)